IL263174A - Preparations containing cannabidiol and hyaluronic acid for the treatment of inflammatory joint diseases - Google Patents

Preparations containing cannabidiol and hyaluronic acid for the treatment of inflammatory joint diseases

Info

Publication number
IL263174A
IL263174A IL263174A IL26317418A IL263174A IL 263174 A IL263174 A IL 263174A IL 263174 A IL263174 A IL 263174A IL 26317418 A IL26317418 A IL 26317418A IL 263174 A IL263174 A IL 263174A
Authority
IL
Israel
Prior art keywords
treatment
hyaluronic acid
preparations containing
joint diseases
inflammatory joint
Prior art date
Application number
IL263174A
Other languages
Hebrew (he)
Inventor
Tamir Gedo
Original Assignee
Tamir Gedo
Bol Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tamir Gedo, Bol Pharma Ltd filed Critical Tamir Gedo
Publication of IL263174A publication Critical patent/IL263174A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL263174A 2016-05-24 2018-11-21 Preparations containing cannabidiol and hyaluronic acid for the treatment of inflammatory joint diseases IL263174A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662340576P 2016-05-24 2016-05-24
PCT/IL2017/050580 WO2017203529A1 (en) 2016-05-24 2017-05-24 Compositions comprising cannabidiol and hyaluronic acid for treating inflammatory joint diseases

Publications (1)

Publication Number Publication Date
IL263174A true IL263174A (en) 2018-12-31

Family

ID=60411168

Family Applications (1)

Application Number Title Priority Date Filing Date
IL263174A IL263174A (en) 2016-05-24 2018-11-21 Preparations containing cannabidiol and hyaluronic acid for the treatment of inflammatory joint diseases

Country Status (4)

Country Link
EP (1) EP3463304A4 (en)
CA (1) CA3025208A1 (en)
IL (1) IL263174A (en)
WO (1) WO2017203529A1 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2568929A (en) 2017-12-01 2019-06-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
CA3105082A1 (en) * 2018-07-02 2020-01-09 Companion Sciences, Llc Cannabidiol combination compositions
WO2020021545A1 (en) * 2018-07-25 2020-01-30 Bol Pharma Ltd. Cannabidiol and glucosamine for treating inflammatory joint diseases
WO2020024056A1 (en) * 2018-08-01 2020-02-06 Lazar Eve Compositions comprising cannabinoids and absorbable material and uses thereof
WO2020077103A1 (en) * 2018-10-10 2020-04-16 Tilray, Inc. Methods and formulations for treating chemotherapy-induced nausea and vomiting
CA3119037A1 (en) * 2018-12-11 2020-06-18 Disruption Labs Inc. Compositions for the delivery of therapeutic agents and methods of use and making thereof
EP3935036A1 (en) * 2019-03-05 2022-01-12 Colleen Smith Veterinary compositions and methods of use therefor
EP3937925A1 (en) 2019-03-12 2022-01-19 EPM (IP), Inc. Cannabinoid acid ester compositions and uses thereof
US20200352849A1 (en) * 2019-05-07 2020-11-12 Adam M. Rotunda Topical Skin Formulations and Wound Care Products with Integrated CBD Delivery Mechanisms for Skin Rejuvenation, Wound Care and Healing, Pain and Itch Relief, and Scar Prevention and Treatment
IT201900008409A1 (en) * 2019-06-07 2020-12-07 Vivatis Pharma Gmbh Identification and selection of a vegetable starting material of chondroitin sulfate and vegetable hyaluronic acid, and transformation of this vegetable starting material to obtain ingredients for use in foods, supplements, medical devices or drugs
WO2021064730A1 (en) 2019-10-03 2021-04-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Liposomal cannabinoids and uses thereof
WO2021091905A1 (en) * 2019-11-08 2021-05-14 Vella Bioscience, Inc. Liposomal formulations for delivery of cannabinoids and methods of making thereof
JP2023510089A (en) * 2019-12-13 2023-03-13 フォリウムラボ インコーポレーティッド Complexes Comprising Carbohydrate Polymers and Active Ingredients and Methods for Their Preparation
GB201918846D0 (en) * 2019-12-19 2020-02-05 Gw Res Ltd Oral cannabinoid formulations
EP3861996A1 (en) 2020-02-04 2021-08-11 I+Med S. Coop. Controlled release system of phytocannabinoids formulations soluble in aqueous media, methods and uses thereof
CN112138138B (en) * 2020-11-19 2023-05-23 乐康珍泰（天津）生物技术有限公司 Pharmaceutical composition for treating gout and preparation method thereof
US12029720B2 (en) 2021-04-29 2024-07-09 Tilray Brands, Inc. Cannabidiol-dominant formulations, methods of manufacturing, and uses thereof
WO2022232897A1 (en) * 2021-05-03 2022-11-10 Panag Pharma Inc. Topical liposome polyphenol compositions for treating and preventing various skin disorders and methods of preparation thereof
IT202200002000A1 (en) * 2022-02-04 2023-08-04 Mak Pharma S R L Liposomal oral composition of at least one active ingredient that is poorly absorbable at the intestinal level

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5128326A (en) * 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
US10004684B2 (en) * 2001-02-14 2018-06-26 Gw Pharma Limited Pharmaceutical formulations
US20040018237A1 (en) * 2002-05-31 2004-01-29 Perricone Nicholas V. Topical drug delivery using phosphatidylcholine
GB2414933B (en) * 2004-06-08 2009-07-15 Gw Pharma Ltd Cannabinoid compositions for the treatment of disease and/or symptoms in arthritis
ES2534900T3 (en) * 2007-07-30 2015-04-30 Zynerba Pharmaceuticals, Inc. Cannabidiol prodrugs, compositions comprising cannabidiol prodrugs and methods of use thereof
EP2227085A4 (en) * 2007-12-06 2013-10-09 Berg Pharma Llc Inhalable compositions having enhanced bioavailability
TWI382841B (en) * 2010-10-29 2013-01-21 Univ China Medical Pharmaceutical composition for inhibiting inflammation
US20130184354A1 (en) * 2012-01-13 2013-07-18 Donna K. Jackson Silicone and Hylauronic Acid (HLA) Delivery Systems for Products by Sustainable Processes for Medical Uses Including Wound Management
US20150004219A1 (en) * 2012-02-02 2015-01-01 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Stable liposomes for drug delivery
HRP20230655T1 (en) * 2012-07-05 2023-10-13 Taiwan Liposome Company, Ltd. Methods of treating arthritis
US20160279073A1 (en) * 2013-10-31 2016-09-29 Full Spectrum Laboratories, Ltd. Terpene and cannabinoid formulations

Also Published As

Publication number Publication date
WO2017203529A1 (en) 2017-11-30
EP3463304A1 (en) 2019-04-10
EP3463304A4 (en) 2020-01-08
CA3025208A1 (en) 2017-11-30

Similar Documents

Publication Publication Date Title
IL269158A (en) Preparations and methods for the treatment of inflammatory diseases
HUE053309T2 (en) New salts and pharmaceutical preparations for the treatment of inflammatory diseases
PL3717471T3 (en) NEW COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM FOR THE TREATMENT OF DISEASES
IL255269A (en) Preparations of obeticholic acid and methods of use
IL256614A (en) Preparations of transthyretin (ttr) irna and methods of using them for the treatment or prevention of ttr-related diseases
IL258955A (en) Preparations and methods for the treatment of cancer
IL262608A (en) Combined treatment of eye disorders and inflammatory diseases
PL3600309T3 (en) THERAPEUTIC COMBINATIONS FOR THE TREATMENT OF LIVER DISEASES
HUE053115T2 (en) Topical pharmaceutical formulations for the treatment of inflammatory conditions
DK3889145T3 (en) 8-cyano-5-piperidino-quinolines as TLR7/8 antagonists and uses thereof for the treatment of immune diseases
GB201517215D0 (en) Use of cannabinoids in the treatment of inflammatory skin diseases
HUE039864T2 (en) Pharmaceutical preparations for the treatment of CFTR-mediated diseases
IL259861A (en) Methods and preparations for the treatment of disorders related to seizures
IL284125A (en) History of quinoline for use in the treatment of inflammatory diseases
PL3169328T3 (en) CHINOLINE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES
IL264070A (en) Methods and preparations for the treatment of disorders and diseases involving rdh12
DK3509638T3 (en) Preparations containing cannabidiol acid esters and uses thereof
HUE060496T2 (en) Therapeutic compounds and preparations for the treatment of social disorders and substance use disorders
IL258259A (en) Complementary treatment with the help of hydroxyvitamin d and preparations that include it
IL272601A (en) Pharmaceutical preparations for the treatment of ophthalmic conditions
PL3381451T3 (en) PHARMACEUTICAL COMPOSITION USED FOR REDUCTION OF LOCALIZED ADIPOSITE TISSUES AND USE OF THE PHARMACEUTICAL COMPOSITION
IL233639B (en) Preparations and methods for the treatment of diseases and liver disorders
IL268720A (en) Formulations of cannabinoids for the treatment of dermatitis and inflammatory skin diseases
IL269083A (en) Methods for the prevention and treatment of heart diseases
IL248779A0 (en) Pharmaceutical preparations for the treatment of infectious diseases